ACHE and Alzheimer disease: Despite the recent and much-debated approval of Aducanumab by FDA for AD treatment, Acetyl-cholinesterase-inhibitors (AChEIs), such as donepezil, galantamine and rivastigmine, represent the first line pharmacological treatment options in patients with AD, with the aim of treating symptoms and slowing the natural course of the disease3–5.